SG11202003127WA - Methods for treating lymphomas - Google Patents

Methods for treating lymphomas

Info

Publication number
SG11202003127WA
SG11202003127WA SG11202003127WA SG11202003127WA SG11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA
Authority
SG
Singapore
Prior art keywords
methods
treating lymphomas
lymphomas
treating
Prior art date
Application number
SG11202003127WA
Inventor
Choon Kiat Ong
Soon Thye Lim
Jing Quan Lim
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11202003127WA publication Critical patent/SG11202003127WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202003127WA 2017-10-06 2018-10-08 Methods for treating lymphomas SG11202003127WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201708262R 2017-10-06
PCT/SG2018/050509 WO2019070204A1 (en) 2017-10-06 2018-10-08 Methods for treating lymphomas

Publications (1)

Publication Number Publication Date
SG11202003127WA true SG11202003127WA (en) 2020-05-28

Family

ID=65994265

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003127WA SG11202003127WA (en) 2017-10-06 2018-10-08 Methods for treating lymphomas

Country Status (6)

Country Link
US (1) US20200325229A1 (en)
EP (1) EP3692174A4 (en)
JP (1) JP2020536111A (en)
CN (1) CN111479932A (en)
SG (1) SG11202003127WA (en)
WO (1) WO2019070204A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022241293A2 (en) * 2021-05-14 2022-11-17 Foundation Medicine, Inc. Cd274 mutations for cancer treatment
CN114507286B (en) * 2022-04-18 2022-07-05 苏州百道医疗科技有限公司 anti-PD-L1 recombinant rabbit monoclonal antibody and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150292022A1 (en) * 2011-11-25 2015-10-15 Singapore Health Services Pte Ltd. Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
CA2952181A1 (en) * 2014-05-28 2015-12-03 Dana-Farber Cancer Institute, Inc. Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response
WO2016175275A1 (en) * 2015-04-30 2016-11-03 国立大学法人京都大学 Method for predicting therapeutic effect of pd-1/pd-l1 inhibitor using abnormality in pd-l1(cd274) as index
CN106987631A (en) * 2017-04-01 2017-07-28 武汉赛云博生物科技有限公司 A kind of immune group sequencing technologies for the adjoint diagnosis of PD 1/PD L1 blocking treatments

Also Published As

Publication number Publication date
CN111479932A (en) 2020-07-31
US20200325229A1 (en) 2020-10-15
EP3692174A4 (en) 2021-06-23
EP3692174A1 (en) 2020-08-12
JP2020536111A (en) 2020-12-10
WO2019070204A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
HK1251407A1 (en) Methods for treating cancer
ZA201705673B (en) Methods for treating skin
ZA201706616B (en) Method for treating cancer
IL249454B (en) Treating lymphomas
IL304252A (en) Method for treating cancer
IL289947A (en) Method for treating cancer
IL257691A (en) Method for treating cancer
HK1244217A1 (en) Methods for treating proteinopathies
HK1254258A1 (en) Methods for treating cancer using apilimod
HK1250944A1 (en) Methods for treating cancer
GB2567616B (en) Treatment method
HK1248135A1 (en) Combination method for treating cancer
HK1248133A1 (en) Methods for treating neuroblastoma
HK1250942A1 (en) Methods for treating cancer
GB2571601B (en) Treatment method
HK1250943A1 (en) Methods for treating cancer
SG11202001806TA (en) Treatment method
SG11202003127WA (en) Methods for treating lymphomas
IL270867A (en) Treatment method
SG10201508795XA (en) Method for treating cancer
HK1256371A1 (en) Methods for treating tumours
HUP1700275A2 (en) Process for self-host